Altogether these observations imply that STAT3-JAK2 fusion protein is not important only as a diagnostic biomarker but also as a potential therapeutic target in CD4+ indolent GI T-LPD cases having this genetic lesion. The gene discussed is JAK2; the disease is disseminated peritoneal leiomyomatosis.